Latest News and Press Releases
Want to stay updated on the latest news?
-
Hamilton, Bermuda, April 25, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
-
Hamilton, Bermuda, April 15, 2019 (GLOBE NEWSWIRE) -- Hamilton, Bermuda, April 15, 2019 – Auris Medical Holding Ltd. (Nasdaq: EARS), a clinical-stage company dedicated to developing therapeutics...
-
Auris Medical Announces Randomization of First Dose Cohort in AM-201 Phase 1b Proof-of-Concept Study
Hamilton, Bermuda, March 29, 2019 - Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
-
Zug, Switzerland, March 15, 2019 (GLOBE NEWSWIRE) -- March 14, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important...
-
Zug, Switzerland, March 14, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
-
Phase 1 trial confirmed superior bioavailability of intranasal betahistine as well as good safety and tolerability Intranasal betahistine program progressing towards proof-of-concept studies in...
-
Zug, Switzerland, March 11, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
-
Zug, Switzerland, March 07, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
-
Hearing Requested to Present Compliance Plan Zug, Switzerland, February 8, 2019 - Auris Medical Holding AG (Nasdaq: EARS), a clinical-stage company dedicated to developing therapeutics that...
-
Zug, Switzerland, February 1, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...